Hao Chen

Dr. Hao Chen


Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 October 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
CSChen Shen
Chen Shen
DLDeze Li
Deze Li
HCHao Chen
Hao Chen
Background: Expression quantitative trait loci (eQTLs) carry a disproportionate share of autoimmune disease heritability, yet whether genetic regulation differs across inflammatory diseases within one cell type is unknown. Cross-disease comparison of monocyte eQTLs has not been performed with harmonized processing and power-calibrated specificity, and the ten-fold range of cohort sample sizes makes naive comparisons vulnerable to false specificity.Methods: We harmonized monocyte cis-eQTL summary statistics from five public resources spanning healthy, lupus-enriched, influenza-stimulated, and inflammatory bowel disease contexts; quantified power and false specificity by simulation; and decomposed effect sharing with multivariate adaptive shrinkage (mashR) and a variance-based specificity index.Results: In simulation, naive per-condition significance calls misclassify 72.6% of truly shared eQTLs as disease-specific; cross-condition borrowing reduces this to 13.0%, and a high-confidence specificity criterion to 0.005%. A three-condition pilot run (1,671,712 gene–variant pairs) passed all quality-control gates, and the full-scale seven-condition run (3,277,117 pairs) confirmed the patterns at scale across the healthy, SLE-cohort, and influenza axes: data-driven covariance structures dominated the fitted mixture (combined weight 0.9471), 2,737,644 pairs (83.5% of the strong set) remained significant under the joint model, and 16.87% of pairs were high-confidence specific under the tested-mask-aware criterion (16.90% after adjudication-layer MHC exclusion), within the pre-registered 20% ceiling under both configurations and in all 18 cells of the adjudication sensitivity grid, with MHC-region and 17q21.31 genes top-ranked. Magnitude sharing was highest within studies (within-study mean 0.859 versus cross-study mean 0.345; Randolph non-infected versus influenza-exposed 0.953, Perez classical versus non-classical 0.899). Pre-registered arbitration diagnostics (PCA and hierarchical clustering of the posterior mean matrix) grouped conditions by study of origin rather than by health-versus-disease status; under the pre-registered scenario-C rule, cross-cohort disease-specificity claims therefore contract to within-study paired contrasts. In the paired Randolph cohort—the single design in which disease state is unconfounded with cohort—influenza exposure and infection left the monocyte eQTL landscape nearly intact: sign concordance between the non-infected and infected states was 99.7% among jointly significant pairs, magnitude sharing was 0.89–0.95, and effect amplitudes were attenuated with infection (median posterior-effect ratio, non-infected over infected, 1.31), while 71,107 pairs (2.2% of the strong set) were high-confidence specific to the influenza axis. Conclusions: This study establishes and validates a power-calibrated framework for cross-disease regulatory genetics at full scale. Because disease context is confounded with cohort, ancestry, and platform in the current design and the pre-registered discriminating diagnostics show study-of-origin grouping, cross-cohort disease-specificity claims contract to within-study paired contrasts under the pre-registered rule. Within the one paired disease-state design available, influenza exposure and infection produce graded amplitude modulation on an almost completely shared regulatory backbone rather than wholesale regulatory rewiring; whether healthy-reference maps systematically miss disease-context regulation beyond such amplitude effects cannot be decomposed from cohort effects here. Disease-stratified heritability partitioning and locus-level nomination are pre-registered and in progress.

28 October 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
HCHao Chen
Hao Chen
DLDeze Li
Deze Li
WXwang xiaotong
wang xiaotong
CSChen Shen
Chen Shen
Mycoplasma pneumoniae pneumonia (MPP) has re-emerged globally since 2023, with macrolide-resistant M. pneumoniae (MRMP) exceeding 80% of isolates in China and the Republic of Korea; because tetracyclines and fluoroquinolones are age-restricted in children, no guideline-endorsed antibiotic class outside Japan combines reliable activity against resistant strains with an unrestricted pediatric safety profile. Macrolide resistance prolongs fever and hospitalization without worsening severity, implicating dysregulated host inflammation in the residual burden. We derived an MPP host disease signature from public pediatric transcriptomes and prioritized approved compounds through four executed evidence layers: pathway enrichment, network proximity, LINCS L1000 signature reversal, and literature triangulation. Re-analysis of the largest MPP blood cohort identified 159 differentially expressed genes, and the age-adjusted MPP-versus-viral model reproduced the published signature (2,976 shared genes, 99.8% concordance). The target map converges on NLRP3-IL-1β-pyroptosis and JAK-STAT axes, with a transcriptome-supported AIM2 signal; doxycycline (z = -3.81) was significantly proximal to the disease module, whereas quercetin (z = -3.03) is discounted for annotation-density artifacts. Corticosteroids anchor Tier 1, and JAK inhibitors are the highest-priority testable hypothesis. This hypothesis-generating framework provides a reproducible template for host-directed repurposing in antimicrobial-resistant pediatric respiratory infections.

26 October 2026 in Microorganisms
Verified
Journal Article
Open access
PDF file
HCHao Chen
Hao Chen
DLDeze Li
Deze Li
CSChen Shen
Chen Shen
We characterized respiratory pathogen shifts across 71,509 pediatric respiratory admissions (2016–2023) at a tertiary children’s hospital in Beijing, China, spanning the complete COVID-19 non-pharmaceutical intervention cycle. Mycoplasma pneumoniae detection rebounded 10.2-fold, from 5.3% during late intervention to 54.2% after reopening, exceeding the pre-pandemic baseline (25.3%); macrolide resistance reached 98.8%. Among categorized respiratory fungal records, 86.5% were Candida species, and pharmacologic immunosuppression—rather than autoimmune disease itself—was linked to both fungal record burden and detection of fungi with invasive potential. First-time bronchiolitis obliterans admissions showed 47.7% MP positivity versus 23.0% in non-BO admissions, with positivity highest in the 30 days before BO diagnosis (63.1%) and declining thereafter. Co-infection among fully tested children rose from 11.5% to 28.2%. While macrolide resistance was not the primary driver of the BO increase, the near-universal resistance among rebounding MP strains (98.8%) significantly complicated clinical management. Postintervention rebound was dominated by macrolide-resistant MP with increased polymicrobial co-detection, informing empiric treatment and fungal stewardship decisions.

28 October 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
HCHao Chen
Hao Chen
DLDeze Li
Deze Li
CSChen Shen
Chen Shen
Objectives: Tuberculosis (TB) in children is preventable and curable yet weakly diagnosed, notified, and monitored only to age 14 years. We analyzed the 0–19-year TB burden in the Global Burden of Disease Study (GBD) 2023. Methods: We aggregated deaths and incident cases (95% uncertainty intervals [UIs]), 1990–2023, for four age bands across 204 countries, 21 regions and five Socio-demographic Index (SDI) quintiles; computed trends, pandemic-window changes with Monte Carlo–propagated uncertainty, and fixed-2021 SDI gradients, benchmarking against WHO estimates and End TB 2025 milestones. Results: In 2023, TB caused 87,764 deaths (95% UI 65,765–109,764) at ages 0–19 years—about 240 daily—and 1,665,272 incident cases; deaths fell 65.5% since 1990. Low- plus low-middle-SDI countries carried 90.3% of deaths across a 531-fold mortality gradient. GBD 0–14-year mortality was 39.9% of the like-for-like WHO estimate (66,146 vs 166,000); incidence agreed closely (80.8%). Deaths fell 23.9% over 2015–2023 against the 75% milestone. Adolescents aged 15–19 years improved slowest. Conclusions: Measurement systems disagree 2.5-fold on pediatric TB deaths, milestones are off track three-fold, and the burden concentrates where monitoring is weakest. Reconciling estimation, extending monitoring to ages 15–19 years, and concentrating resources on high-burden countries are prerequisites for ending TB in children.

28 October 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
DLDeze Li
Deze Li
HCHao Chen
Hao Chen
CSChen Shen
Chen Shen
Background: Upper respiratory infections (URIs) are the most frequent illnesses of childhood, yet mortality-anchored child-health monitoring excludes high-frequency, low-fatality conditions. No dedicated pediatric assessment of the global URI burden exists for the Global Burden of Disease Study (GBD) 2023. We quantified URI incidence and mortality at ages 0–19 years, 1990–2023. Methods: We extracted deaths and incident episodes for the GBD cause “upper respiratory infections” from the GBD 2023 Results Tool for the under-5 aggregate plus the 5–9-, 10–14-, and 15–19-year bands, 21 regions, and five Socio-demographic Index (SDI) quintiles, 1990–2023. Crude rates used back-calculated populations; trends used estimated annual percentage change (EAPC). URI was positioned against diarrhoeal diseases, asthma, lower respiratory infections (LRI), and tuberculosis. Results: In 2023, URIs caused 5.616 billion incident episodes (95% uncertainty interval [UI] 4.133–7.330 billion) at ages 0–19 years—210,275 per 100,000, about 2.1 episodes per child per year—against 16,382 deaths (1,781–57,834), a case-fatality proxy of 0.00029%. URIs outnumbered LRI episodes 69.3-fold, while LRI deaths exceeded URI deaths 43.4-fold. Since 1990, incident episodes rose 9.8% in number while the rate declined only 7.3% (EAPC −0.27% per year, one-eleventh of the LRI pace); deaths fell 39.6% (rate EAPC −1.90%). Under-5 children accounted for 34.5% of episodes (three per child per year) and 85.7% of deaths. Incidence rates were nearly flat across SDI quintiles (183,913–255,578 per 100,000), whereas mortality fell 66-fold from low to high SDI (1.724 vs 0.026 per 100,000); the low-SDI quintile carried 89.2% of deaths. Conclusions: The world’s most common pediatric infection is also its least monitored: incidence has stalled for three decades, while a small but real mortality toll concentrates in under-5 children in low-SDI settings. URI merits inclusion in child-health monitoring as a morbidity and antibiotic-stewardship indicator and improved cause-of-death certification where fatal respiratory illness is coded to the upper airway.

28 October 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
CSChen Shen
Chen Shen
WXwang xiaotong
wang xiaotong
HCHao Chen
Hao Chen
DLDeze Li
Deze Li
Background: Retinoblastoma is the most common primary intraocular malignancy of childhood and is nearly universally curable where effective services exist: three-year survival is 99.5% in high-income countries versus 57.3% in low-income countries. Because its occurrence is largely non-modifiable while its outcome is highly treatment-dependent, retinoblastoma is among the most sensitive tracers of childhood cancer cure capacity. We quantified its global burden, trends, and diagnosis–outcome gap. Methods: We analysed Global Burden of Disease (GBD) Study 2023 estimates (results release v8352) for retinoblastoma (cause_id 1009). Deaths and incident cases at ages 0–19 years — the sum of the <5, 5–9, 10–14, and 15–19-year bands — were extracted for the global level, 21 regions, and five Socio-demographic Index (SDI) quintiles over 1990–2023, with a national map for 204 countries in 2022. The mortality-to-incidence ratio (M/I) served as a proxy for cure. Reporting follows GATHER. Results: In 2023, retinoblastoma caused 3,226 deaths (95% uncertainty interval [UI] 1,493–6,569) at ages 0–19 years, down 31.8% from 1990; the crude death rate declined significantly (estimated annual percentage change [EAPC] −1.48% per year, 95% CI −1.60 to −1.36), while the incident case count rose significantly (EAPC +0.63%, 95% CI 0.40 to 0.87). The global M/I fell from 87.4% to 55.5%, yet the low-to-high SDI M/I ratio widened from 3.1-fold to 13.0-fold — the widest disparity among 14 childhood cancers by point estimate (95% UI 3.02–39.65). Children under 5 years accounted for 87.7% of deaths (95% UI 67.1–96.1). The cross-SDI mortality gradient (18.8-fold) far exceeded the incidence gradient (1.5-fold). Conclusions: Residual retinoblastoma mortality is concentrated almost entirely in children under 5 years in low-SDI settings and is consistent with an outcome-driven divide rooted in diagnostic delay and treatment access. Community-level recognition of leukocoria offers the highest-leverage intervention, and the M/I provides a measurable indicator for monitoring the WHO Global Initiative for Childhood Cancer.